48. Biosimilars - a podcast by American College of Rheumatology

This week we discuss what a biosimilar is, why they’re causing such controversy and why they’ve taken seven years, since the FDA approved Amgevita, to come to market. We review the evidence behind the safety and efficacy of these drugs, the data from switching from a bio-originator to a biosimilar, and how the approval of the drugs may lower the health care costs and improve access to these medications. 

Further episodes of ACR on Air

Further podcasts by American College of Rheumatology

Website of American College of Rheumatology